Letter: Antioestrogens in treatment of breast cancer

Stoll, B A
May 1974
British Medical Journal;5/25/1974, Vol. 2 Issue 5916, p447
Academic Journal
No abstract available.


Related Articles

  • Antioestrogens and breast cancer. Santhanam, S.; O'Byrne, K. J. // Journal of the British Menopause Society;2001, Vol. 7 Issue 1, p21 

    Antioestrogens are among the most widely used agents in the treatment of breast cancer. There has been a recent surge of interest in these compounds because of their potential breast cancer chemopreventive properties. The newer generation of antioestrogens, with increased selectivity and better...

  • anti-oestrogen drugs. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p58 

    An encyclopedia entry for an "anti-oestrogen drugs" is presented. They refer to a group of drugs that contrast the action of the hormone oestrogen. Tamoxifen, which is used in the treatment of certain breast cancers, is said to be the most important of these drugs.

  • Adjuvant Therapy with Curative Intent: Is That Really So? Mangalik, Aroop // Internet Journal of Oncology;2009, Vol. 6 Issue 1, p1 

    A letter to the editor is presented discussing breast cancer treatment.

  • ONCOLOGY. Kanaike, Megumi // Journal of Pharmacy Practice & Research;Mar2010, Vol. 40 Issue 1, p72 

    The article presents abstracts on oncology topics including the use of risedronate to prevent bone loss resulting from aromatase inhibitors, the use of cetuximab and radiotherapy for the treatment of advanced head and neck cancer and the use of acupuncture in breast cancer patients receiving...

  • Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Kunisue, H; Kurebayashi, J; Otsuki, T; Tang, C K; Kurosumi, M; Yamamoto, S; Tanaka, K; Doihara, H; Shimizu, N; Sonoo, H // British Journal of Cancer;1/1/2000, Vol. 82 Issue 1, p46 

    Anti-oestrogen is effective for the treatment of oestrogen receptor (ER)-positive breast carcinomas, but most of these tumours become resistant to anti-oestrogen. It has been suggested that anti-oestrogen therapy may induce a HER2 signalling pathway in breast cancer cells and this may cause...

  • ERRATUM: ANTI-OESTROGENIC PREVENTION OF BREAST CANCER — THE MAKE OR BREAK POINT. Powles, Trevor J. // Nature Reviews Cancer;Dec2002, Vol. 2 Issue 12, p964 

    Presents a correction of the error made in the article on anti-oestrogenic prevention of breast cancer published in the December 2002 issue of the 'Nature Reviews' journal.

  • AstraZeneca breast cancer drug gains marketing approval in EU.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p7 

    Reports that AstraZeneca PLC has received European marketing approval for its breast cancer drug Faslodex, which is indicated for the treatment of advanced breast cancer in post-menopausal women whose cancer has progressed on previous anti-oestrogen treatments. Company's plan to launch Faslodex...

  • Anti-oestrogen therapy modified risk of melanoma after breast cancer.  // Australian Journal of Pharmacy;Jun2012, Vol. 93 Issue 1105, p85 

    The article informs about cohort studies according to which women diagnosed with breast cancer and receiving anti-oestrogen therapy are at higher risk of melanoma after breast cancer.

  • Acute coronary syndrome in a breast cancer patient treated with tamoxifen. Benbrahim, Zineb; Arifi, Samia; Boudahna, Lamiae; Amaadour, Lamiae; Sekkali, Naim; Lahlou, Ikram; Akoudad, Hafid; Mellas, Nawfel; El Mesbahi, Omar // Pan Arab Journal of Oncology;Jun2014, Vol. 7 Issue 2, p10 

    Tamoxifen is a non-steroidal antioestrogen widely used in the treatment of breast cancer. Prolonged exposure to this therapy may result in cardio vascular undesirable events particularly thrombotic events. Arterial effects are rare. We report a case acute coronary syndrome in a locally advanced...

  • Opinion: Anti-oestrogenic prevention of breast cancer — the make or break point. Powles, Trevor J. // Nature Reviews Cancer;Oct2002, Vol. 2 Issue 10, p787 

    Clinical trials have shown that giving anti-oestrogens to healthy women can reduce the early incidence of breast cancer by ∼40%. However, the large numbers of women treated, compared with the few who get breast cancer, together with the not insignificant toxicity and the unknown long-term...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics